Trial · NCT06812065
Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts
NCT06812065, Not applicable, Recruiting, First Hospital of China Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts. Trials, record NCT06812065. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06812065
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts
- NCT number
- NCT06812065
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 300 participants, estimated
- Lead sponsor
- First Hospital of China Medical University
- Conditions
- Warts
- Interventions
- Hydrogen Peroxide 3 % Topical Solution, Local Hyperthermia at 44℃
- First posted
- 2025-02-06
- Last updated
- 2026-09-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete clearance rate of warts | 6 months after the first time of treatment. | The complete clearance rate was defined as the proportion of patients with lesions that completely disappeared within 6 months of completing all treatments. |
| Primary | Time to complete clearance | 6 months after the first time of treatment. | Median duration from first treatment to complete resolution (days) |
| Primary | Recurrence rate of warts | recurrence was the proportion of patients with reappearance of lesions at previously cleared sites within 6 months after treatment. | Complete clearance was defined as the proportion of patients with complete disappearance of lesions within 6 months of completion of all treatments, and recurrence was the proportion of patients with recurrence of lesions at the cured lesion site within 6 and 12 months after treatment, |
| Secondary | Changes in the size and number of warts at different points in time | At 1 week, 2 weeks, 3 weeks, 4 weeks, 12 weeks, 24 weeks follow-up | Changes in the size and number of warts at different time points (1 week, 2 weeks, 3 weeks, 4 weeks, 12 weeks, 24 weeks) |
| Secondary | Curative effect of different types of warts | followed up at 6 months | The cure of different types of warts (common warts, plantar warts, condyloma acuminatum) was followed up at 6 months. |
| Secondary | Occurrence of adverse events | During treatment and follow-up | occurrence of adverse events (short - and long-term adverse reactions) (e.g. blisters, erythema, nail changes, ulcers/scars, hyperpigmentation, hypopigmentation, erosion) |
| Secondary | Treatment-related pain intensity | During each treatment session (Day 1, 2, 3, 10, 11, 18, 19) | Pain assessed by Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain) |
| Secondary | Patient satisfaction score | At 6-month follow-up | Self-reported satisfaction on a 5-point Likert scale (0=very dissatisfied, 5=very satisfied) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06812065
GET https://conductscience.org/api/trials/v1/NCT06812065/registered